Develops antibodies for cancer treatments
Symphogen has raised €282M across 6 funding rounds from 5 investors, most recently a Debt round in Oct 2015. Based in Ballerup, Denmark; founded 2000; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2015-10-01 | Debt | €68M | Novo A,S | View deal → |
| 2013-05-01 | Growth/Late | €41M | Novo A,S | View deal → |
| 2011-02-01 | Series D+ | €100M | Essex Woodlands Health Ventures,Novo A,S | View deal → |
| 2009-02-01 | Growth/Late | €33M | Essex Woodlands Health Ventures | View deal → |
| 2006-01-01 | Series D+ | €21M | Essex Woodlands Health Ventures,Gilde Healthcare,Novo A,S,Takeda Ventures | View deal → |
| 2004-11-01 | Series C | €20M | Essex Woodlands Health Ventures,Novo A,S | View deal → |
